Estradiol

Product matters

Certain products treat menopausal hot flushes, vaginal symptoms or low-estrogen conditions. Some have additional bone-prevention or palliative cancer indications. Those uses do not apply to every estradiol product.^267,268,269

Hormone forms and medicines

Estradiol is a nonpeptide estrogen. Valerate, cypionate and acetate products release estradiol but have their own formulations and uses; conjugated estrogens and ethinylestradiol are different drugs.^{270,271,272,273}

Relief measured in a trial

Hot-flush improvement was the direct clinical outcome; heart-disease and dementia prevention fall outside that result.

Oral estradiol		52.9%
Venlafaxine		47.6%
Placebo		28.6%

Percent reduction from baseline. MsFLASH randomized 339 perimenopausal and postmenopausal women: 97 to oral estradiol 0.5 mg/day, 96 to oral venlafaxine 75 mg/day and 146 to placebo. These are study exposures.²⁸⁹

Placebo comparison

Estradiol reduced symptom frequency by 2.3 more episodes per day than placebo. Its advantage over venlafaxine was 0.6 per day and was not statistically significant (P = 0.09).²⁸⁹

Where trials found limits

A biological effect, symptom change and prevention of disease are different outcomes.

One vaginal-symptom trial found no added benefit

In a 12-week randomized trial of 302 postmenopausal women, a vaginal estradiol tablet and a moisturizer each failed to outperform dual placebo for the most bothersome vulvovaginal symptom. Symptoms improved in all three groups. That result concerns the tested products and comparison; it does not erase other product trials or approvals.²⁹⁸

Artery-scan endpoints

KEEPS randomized 727 recently menopausal women. After four years, neither transdermal estradiol with progesterone nor oral conjugated estrogens with progesterone changed carotid-wall thickening versus placebo. ELITE randomized 643 women and found slower thickening with oral estradiol in the early-menopause group, but not the later group. These imaging findings do not establish prevention of heart attacks.^299,300

Cognition and mood evidence

KEEPS-Cog enrolled 693 women and found no cognitive benefit; mood outcomes with transdermal estradiol were similar to placebo. The mood improvement reported with oral conjugated estrogens cannot be assigned to estradiol. In ELITE’s cognitive analysis of 567 women, oral estradiol did not improve verbal memory, executive function or global cognition versus placebo.^301,302

Route comparisons

The evidence favors careful distinctions between medicines and outcomes.

ESTHER observational result

In 271 postmenopausal women with a first venous blood clot and 610 controls, current oral estrogen use was associated with higher odds than nonuse: 4.2 (95% CI 1.5-11.6). The estimate for transdermal estrogen was 0.9 (0.4-2.1). This observational study does not prove patches carry no clot risk.²⁹⁰

A newer Danish study

A September 2026 analysis found higher thrombotic risks with oral menopausal hormone therapy. Transdermal treatment was generally not associated with higher rates, but cyclic combined transdermal treatment had an increased myocardial-infarction estimate: HR 2.1 (95% CI 1.1-4.1). These findings were associations in Danish women aged 50-69; the analysis was not randomized.²⁹¹

Other clinical settings

Other clinical settings use estradiol for purposes and outcomes beyond menopause symptoms.

87.1% vs 85.9%

Among 1,360 men with locally advanced prostate cancer, three-year metastasis-free survival was 87.1% with transdermal estradiol and 85.9% with LHRH agonists. Estradiol met the trial’s noninferiority criterion; this does not establish superiority. This was specialist cancer treatment.²⁹³

Side-effect patterns

In that trial, hot flushes occurred in 44% with estradiol and 89% with LHRH agonists; gynecomastia occurred in 85% and 42%. These results cannot be transferred to menopausal or gender-affirming treatment.²⁹³

Serum levels and outcomes

A 2025 systematic review included 49 studies of feminizing hormone therapy. It found no studies demonstrating that the commonly recommended estradiol concentration range produced optimal feminization or fewer adverse events. That uncertainty does not make monitoring unnecessary or justify raising a dose.²⁹⁴

China, Russia and Japan

These sources cover bone density, cognition and fertility care.

China: bone density in a small trial

A study enrolled 60 healthy women one to five years after natural menopause; 56 completed two years of follow-up. All four groups received transdermal estradiol gel with a progestogen. Bone density and symptoms improved, but there was no untreated group and the study did not establish a reduction in fractures.²⁹⁵

Russia: cognition and mood scales

A 2024 study followed 120 women aged 40-50 in four clinical groups: three received treatment and one received none. The authors reported improvements in cognition and mood scales, but randomization and blinding were not established, and the regimens differed in more than their estrogen component.²⁹⁶

Japan: fertility indication

PMDA’s 2022 L-Estrogel review supported uses in assisted reproduction, including hormone-replacement cycles for frozen embryo transfer. The decision relied on established medical knowledge and existing evidence, without a new clinical trial for the application. That fertility indication is specific to the Japanese product decision.²⁹⁷

2026 label changes

FDA approved warning changes for specific products. The current label still needs to be checked by name.

The first label changes

FDA requested menopausal hormone therapy label changes in November 2025 and announced the first six approvals in February 2026. The estradiol-containing products on that initial list are Divigel, Estring and Bijuva.^274,275,276

Remaining warnings

Divigel keeps an endometrial-cancer boxed warning. Estring and Bijuva removed their boxes, but their labels still contain important warnings and contraindications.^268,269,277

The date can mislead

The patch label cited on Reptides has a March 2026 database update date, yet its professional label is revised December 2023 and still carries older boxed wording. The revision inside the label and the database update are separate dates.²⁷⁸

The details that change risk

Benefit evidence is specific to route, uterus status, other medicines and the exact formulation.

The uterus changes the discussion

Unopposed systemic estrogen can stimulate the uterine lining. Divigel’s label addresses adding a progestogen for a woman with a uterus, while Bijuva already combines estradiol and progesterone. Local vaginal products need their own label assessment.^268,277,269

Lamotrigine deserves a specific check

Systemic estrogen treatment can lower lamotrigine concentrations. Medsafe recommended an interaction warning for systemic hormone replacement products, and the Canadian Estradot monograph includes it. The sources do not support a universal dose adjustment.^280,281

Local and systemic exposure

Estring’s label describes lower systemic exposure than systemic estrogen treatment, with uncertainty about how that changes some risks. EMA’s four-week restriction concerns specific high-strength 0.01% vaginal creams; it is not a rule for all vaginal estrogen products.^269,282

Patches, generics and quality

Supply problems and quality findings need a place and a date.

Patch access differs by country

FDA’s September 2026 notice says manufacturers are increasing patch supply and patches remain available despite access difficulties. Australia separately extended a pharmacist substitution instrument through February 2027 because shortages were expected to continue. Neither notice is a self-switching guide.^283,284

Patch testing

Medsafe reported that three sampled Estradot batches met the tested specifications in April 2026. Its investigation remained open, with further testing pending. That result neither certifies every batch nor dismisses an individual adhesion complaint.²⁸⁵

A generic has a specific reference product

FDA announced the first Imvexxy-equivalent generic vaginal insert in December 2025. That approval does not make all estradiol inserts, creams and rings interchangeable.²⁸⁶

Common questions

Products, symptoms, side effects and the practical questions that come up during treatment.

01 Are tablets, patches, vaginal products, estradiol valerate, and estradiol cypionate interchangeable?

No. Oral and transdermal products use estradiol base, vaginal inserts and rings can be local or systemic depending on the product, and intramuscular products use valerate or cypionate esters. Their indications, absorption, excipients, instructions and safety evidence are product-specific.^{267,278,303,271,272,273}

02 Which side effects are common, and which warnings depend on the exact estradiol product?

Headache, breast symptoms, bleeding changes, nausea, skin reactions and local vaginal effects appear in different product records, but their frequencies cannot be pooled across routes. Serious cardiovascular, clotting, cancer, gallbladder and other warnings also remain product-specific. The February 2026 Divigel, Estring and Bijuva labels changed boxed-warning presentation differently and did not erase their remaining warnings or contraindications.^{267,278,303,271,272,268,269,277}

03 Are estradiol patches in shortage, and can a pharmacy substitute another brand or dosage form?

FDA said on September 3, 2026 that some US patients faced localized patch access problems while patches remained available and six manufacturers worked to increase supply. Australia separately extended a formal substitution action through February 28, 2027. Neither notice makes brands, strengths, or dosage forms interchangeable without a pharmacist and prescriber checking the exact products.^283,284

04 When is a progestogen considered with systemic estradiol, and how does hysterectomy change the question?

When a uterus is present, unopposed systemic estrogen increases endometrial-cancer risk, and the checked labels say adding a progestogen reduces endometrial hyperplasia. Hysterectomy usually changes that need, although residual endometriosis and the exact indication can change the decision. Persistent or recurrent unexplained bleeding still needs medical evaluation.^267,278,303

05 Will estradiol predictably change weight, hair, mood, sleep, or libido?

No single route-independent prediction covers that bundle. In menopause, an eight-week randomized trial supports relief of vasomotor symptoms with oral estradiol but does not establish predictable weight, hair or libido changes; in gender-affirming care, the 49-study review found no validated serum target for optimal feminization. Population, product, concurrent hormones, baseline symptoms and the specific outcome define how those findings apply.^289,294,267

06 How long does estradiol take to help, and what happens after it is stopped?

In the current Divigel label’s 12-week randomized trial, the 0.5 g and 1.0 g gel arms, containing 0.5 mg and 1.0 mg estradiol respectively, improved both hot-flush frequency and severity versus placebo by week 4; the 0.25 g gel arm, containing 0.25 mg estradiol, reached both endpoints by week 7, and all three did at week 12. That product-specific result does not supply a timeline for a patch, vaginal product, injection or gender-affirming treatment. Stopping effects also depend on the indication and product, and MHRA’s breast-risk review found that some HRT-associated risk can persist after stopping.^268,304

07 Which menopause symptoms and prevention uses are actually covered by the cited estradiol labels?

Checked systemic labels cover specified moderate to severe vasomotor symptoms, and some also cover selected osteoporosis prevention or vulvovaginal symptoms. When local vulvovaginal symptoms are the only treatment reason, systemic labels direct attention to local vaginal products. None of these records makes estradiol a general treatment for chronic-disease prevention.^{267,278,303,268,269}

08 What does the product information say if an estradiol patch irritates skin, wrinkles, or will not stay attached?

Patch handling and replacement language belongs to the exact product instructions. Medsafe found that three sampled Estradot batches met the tested quality specifications and identified no defect or recall, but that does not disprove an individual adhesion, skin or symptom complaint. A patch that will not stay attached or causes a reaction should be checked with a pharmacist or prescriber instead of being converted to another product by guesswork.^278,285

09 Is there a reliable dose conversion, and what does the exact label say about timing or a missed dose?

No single conversion or missed-dose rule applies across tablets, gels, patches, vaginal products, valerate and cypionate. Each label describes its own product and schedule. When a dose, patch or product change is uncertain, the exact label and the pharmacist or prescriber are the relevant references.^{267,278,303,271,272}

10 Is vaginal estradiol only local, and are inserts, rings, and high-strength creams the same exposure?

No. The cited insert and Estring are local products with some systemic absorption, while Femring is a systemic vaginal ring with a vasomotor-symptom indication. EMA’s four-week restriction applied to named 0.01% high-strength creams, so it cannot be generalized to every vaginal estradiol product.^{303,269,273,282}

11 Do menopause labels and the 2026 FDA MHT changes answer gender-affirming estradiol questions?

No. The FDA records concern product-specific menopause indications, while Italy’s 2020 AIFA determination is a separate specialist-use and reimbursement record for feminizing care. A systematic review of 49 studies found no evidence that a serum estradiol range of 100 to 200 pg/mL produces optimal feminization or fewer adverse events, so menopause labels cannot be turned into a universal gender-affirming regimen or outcome claim.^275,305,294

12 Do estradiol blood levels need monitoring, and is there one target number for every use?

There is no one target concentration across menopause, local vaginal treatment, hypoestrogenism, injected esters and gender-affirming care. The 49-study gender-affirming review did not validate 100 to 200 pg/mL as an outcome-optimal range, and a 562-person injectable-estradiol study showed that sampling timing materially changed measured levels. Interpretation therefore depends on the population, product, timing, symptoms, concurrent hormones and the guidance governing that treatment.^294,306

13 Did the 2026 FDA label changes mean estradiol no longer carries breast, endometrial, heart, or dementia concerns?

No. FDA’s first 2026 changes were product-specific: Divigel retained an endometrial-cancer box and safety text, Estring removed its box while distinguishing lower systemic exposure, and Bijuva removed its box but retained warnings. Medsafe’s committee also said newer evidence did not erase established breast risk, establish substantial cardiovascular benefit or show consistent cognitive benefit.^{268,269,277,279,304}

14 Does a patch have a lower blood-clot risk than oral estrogen, and does that mean the risk is zero?

ESTHER found adjusted VTE odds versus nonuse of 4.2 for current oral estrogen and 0.9 for transdermal estrogen in postmenopausal women, but it was observational. A 2026 Danish nested case-control study also found no overall increase with transdermal therapy, while reporting an exception for myocardial infarction with transdermal combined cyclic therapy, hazard ratio 2.1 with a 95% confidence interval of 1.1 to 4.1. Neither study proves a patch is risk-free or transfers its estimate to injections, vaginal products, other regimens or different populations.^{290,291,267,278}

15 When does bleeding or spotting during estradiol therapy need medical evaluation?

The checked labels treat persistent, recurrent or otherwise unexplained postmenopausal bleeding as needing evaluation to rule out endometrial disease. Bleeding should not be dismissed as an adjustment effect or managed by changing estradiol or progestogen without the prescriber. Bleeding assessment includes product, menopausal status and uterine context.^267,278,303